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Aim To use parallel array pyrosequencing to deconvolute 
mixtures of mitochondrial DNA (mtDNA) sequence and 
provide high resolution analysis of mtDNA heteroplasmy.
Methods The hypervariable segment 1 (HV1) of the mtD-
NA control region was analyzed from 30 individuals using 
the 454 GS Junior instrument. Mock mixtures were used 
to evaluate the system’s ability to deconvolute mixtures 
and to reliably detect heteroplasmy, including heteroplas-
mic differences between 5 family members of the same 
maternal lineage. Amplicon sequencing was performed 
on polymerase chain reaction (PCR) products generated 
with primers that included multiplex identifiers (MID) and 
adaptors for pyrosequencing. Data analysis was performed 
using NextGENe® software. The analysis of an autosomal 
short tandem repeat (STR) locus (D18S51) and a Y-STR lo-
cus (DYS389 I/II) was performed simultaneously with a por-
tion of HV1 to illustrate that multiplexing can encompass 
different markers of forensic interest.
Results Mixtures, including heteroplasmic variants, can be 
detected routinely down to a component ratio of 1:250 (20 
minor variant copies with a coverage rate of 5000 sequenc-
es) and can be readily detected down to 1:1000 (0.1%) with 
expanded coverage. Amplicon sequences from D18S51, 
DYS389 I/II, and the second half of HV1 were successfully 
partitioned and analyzed.
Conclusions The ability to routinely deconvolute mtDNA 
mixtures down to a level of 1:250 allows for high resolu-
tion analysis of mtDNA heteroplasmy, and for differentia-
tion of individuals from the same maternal lineage. The 
pyrosequencing  approach  results  in  poor  resolution  of 
homopolymeric sequences, and PCR/sequencing artifacts 
require a filtering mechanism similar to that for STR stut-
ter and spectral bleed through. In addition, chimeric se-
quences from jumping PCR must be addressed to make 
the method operational.
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The year 2011 marks the 20th anniversary of the use of mi-
tochondrial DNA (mtDNA) sequence analysis in forensic 
identification cases by the Armed Forces DNA Identifica-
tion Laboratory (AFDIL), and the 15th anniversary of the in-
troduction of mtDNA findings in a United States court of 
law by the Federal Bureau of Investigation (FBI) Laboratory 
(Paul William Ware v. State of Tennessee). While the propo-
sition of using mtDNA analysis in casework dates back to 
the late 1980s (1), methods and initial forensic guidelines 
were developed in the early 1990s, leveraging the work 
of  the  ancient  DNA  community  (2-6).  Characteristics  of 
mtDNA biology were investigated throughout the 1990s, 
which led to a better understanding of population diver-
sity, mtDNA mutation rates, and the existence and preva-
lence of mtDNA heteroplasmy (7-16). In addition, the fo-
rensic targets for mtDNA analysis expanded to evidence 
such as crab lice, canines, and entomological specimens 
(17-19). Since that first decade, advanced guidelines for fo-
rensic mtDNA analysis have been published (20-22), whole 
genome  sequencing  approaches  have  been  developed 
(23),  and  movements  have  been  made  toward  analysis 
of mtDNA at the genome level (24). Therefore, the use of 
mtDNA testing to answer questions in forensic investiga-
tions is well established, and continues to provide forensic 
practitioners with a valuable analytical tool.
Historically,  the  principal  targets  for  human  mtDNA  se-
quence  analysis  have  been  the  two  hypervariable  seg-
ments of the control region; HV1 and HV2 (2). Based on 
the numbering system of Anderson et al (25), HV1 encom-
passes positions 16 024-16 365 and HV2 covers positions 
73-340. While considerable work has been done to que-
ry other segments of the control region (26,27), as well as 
strategic positions throughout the entire genome (28,29), 
the vast majority of the discrimination potential is found 
in HV1 and HV2. Segments of the control region between 
16 365-16,569, 1-72, and 341-573 have revealed both single 
nucleotide polymorphisms (SNP) and length-based varia-
tion, and specific wobble positions of the coding region 
possess polymorphic characteristics. Combined, these re-
gions contain a reasonable amount of additional discrimi-
nation power, yet their analysis can require considerable 
additional effort.
The current methods of choice for performing routine fo-
rensic  mtDNA  sequence  analysis  are  polymerase  chain 
reaction  (PCR)  amplification  of  HV1  and  HV2  followed 
by  the  dideoxynucleotide  chain-termination  sequenc-
ing technique of Sanger (30), and the use of capillary 
electrophoresis to analyze the fluorescently tagged 
products (31). The simultaneous sequencing of a pool of 
PCR amplicons generated from a DNA extract produces a 
profile of the predominant component found in the ampli-
con population. Minor components of an mtDNA mixture, 
detected at a level of 5%-20% depending on the analyti-
cal noise in the DNA sequencing instrument, are typically 
observed as a superimposition of two nucleotides at the 
same sequence position or a repetitive series of nucleotide 
residues of various lengths. Each of these heteroplasmic 
types can be difficult to interpret due to the overlapping 
nature of the sequence information, and the sequence of 
length variants downstream of the homopolymeric seg-
ment can be uninterpretable.
Mixtures of mtDNA sequence come from a combination 
of two or more different sources of DNA, or can arise from 
individuals exhibiting heteroplasmy. The existence of het-
eroplasmy, a heterogeneous pool of mtDNA sequences in 
the mitochondria found in the cytoplasm of cells from a 
single individual, was first reported in 1995 (12), and has 
since been studied quite extensively over the last 16 years 
(32-36);  including  the  use  of  alternative  techniques  for 
detection of heteroplasmic variants (37-41). Of particular 
interest, and excitement, is the potential use of second 
generation sequencing (SGS) approaches for the decon-
volution of mtDNA mixtures, including the resolution of 
heteroplasmic variants (42-46).
Of the available SGS technologies (eg, the 454 Life Science 
FLX from Roche, the SOLiD 4 from Applied Biosytems, the 
HiSeq 2000 from Illumina, and the Heliscope Single Mol-
ecule Sequencer from Helicos), the one that may best suit 
targeted sequencing of forensic loci is the 454 Life Scienc-
es system, as it can directly sequence amplicons of 400-500 
bps in length (47,48). Roche has recently released a small 
bench-top instrument (the GS Junior) which is more acces-
sible to forensic laboratories, as the technology costs less 
than US $100 000 to purchase, and the cost per run is less 
than US $1000. The sequencing chemistry is based on a 
pyrosequencing approach (49). Nucleotides flow sequen-
tially across a picotiter plate containing ~ 100 000 reaction 
wells ( ~ 1/10th the capacity of the larger 454 FLX instru-
ment). Each well is ~ 44 μm in diameter and will accom-
modate a single DNA capture bead of ~ 28 μm coated with 
amplified copies of a single original amplicon. The second 
round  of  amplification  occurs  through  a  unique  emul-
sion PCR (emPCR) technique, where each bead attaches 
to a single amplicon molecule, with the emPCR occurring 
in an aqueous micro-droplet containing the PCR reagents 
and surrounded by an oil-based emulsion. During the py-301 Holland et al: Resolving mtDNA mixtures and heteroplasmy
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rosequencing, if a nucleotide is incorporated during the 
sequencing process, a coupled reaction between sulfury-
lase and luciferase will generate photons of light that can 
be captured by a charged-coupled device (CCD) camera. 
When  multiple  nucleotides  are  incorporated  into  a  ho-
mopolymeric stretch, the signal intensity increases, and 
is proportional to the total number of incorporations. The 
pyrosequencing approach and the GS Junior technology 
allows for the parallel sequencing of ~ 100 000 DNA frag-
ments in a single 8-hour run, or is comparable to running 
approximately one thousand 96-well plates of Sanger se-
quencing simultaneously. The result is a level of sequencing 
depth only seen in cloning experiments, at a small fraction 
of the cost and time necessary to complete such a study. 
Therefore, it is clear that the SGS technique from 454 Life 
Sciences has a potential place in forensic investigations.
Thus far, mtDNA sequence analysis has been used primar-
ily in criminal cases involving hair shafts from humans and 
animals, and in cases of identification when skeletal mate-
rial is available or when appropriate references are missing 
for conventional STR analysis. In a relatively high percent-
age of these cases, the presence of mtDNA heteroplasmy 
(both single nucleotide and length-based) can complicate 
profile interpretation. In a much larger percentage of cases, 
the heteroplasmic information is lost due to limitations of 
the traditional dideoxy-Sanger DNA sequencing method. 
In addition, mixtures of mtDNA sequences have histori-
cally not been reported or considered, significantly low-
ering the percentage of cases where mtDNA analysis can 
be, and is applied. When complex issues of heteroplasmy 
or mixtures arise, cloning experiments can often times re-
solve the questions (11), but these studies are quite labor 
intensive, costly, and impractical. Therefore, the purpose 
of the research reported here was to explore the potential 
for using an SGS approach to enhance the detection and 
reportability of mtDNA heteroplasmic variants, and for the 
deconvolution of mtDNA mixtures. Newly developed and 
validated methods for such analysis should increase the 
discrimination potential of the mtDNA typing system, and 
could be more cost-effective than traditional methods cur-
rently in practice. In addition, if the method proves to be ro-
bust, it may be possible to differentiate between maternal 
relatives through the analysis of low-level, de novo hetero-
plasmic variants. Lastly, the SGS approach was assessed for 
its ability to perform STR analysis, including when STR loci 
are multiplexed with the analysis of Y-STR and mtDNA loci. 
The preliminary results from this study were reported at the 
20th International Symposium on Human Identification in 
Las Vegas, NV, sponsored by the Promega Corporation (50).
MetHOds
All  work  for  this  study  was  conducted  under  the  Penn 
State University internal review board (IRB) approved proj-
ect number, 32047. A total of 33 samples were taken from 
related and unrelated individuals in the form of buccal cells 
and whole blood. Each sample was labeled according to 
whether it was from a man or woman, and the order in 
which it was collected. A total of 17 men and 16 women 
were collected, representing 27 different maternal lineages. 
Male (M) samples were given the following tracking num-
bers: M1-5, M7-15, M17-19 (M1 and M2 were not tested for 
this study). Female (F) samples were given the following 
tracking numbers; F1-5, F7-10, F12-13, F16, F22, F25-27 (F1 
was not tested for this study). Genomic DNA was extract-
ed from all samples using an organic-based procedure, 
followed by quantification of human nuclear DNA using 
the Applied Biosystems Quantifiler® assay (Foster City, CA, 
USA). Routine methods of PCR amplification and Sanger 
DNA sequencing were performed to determine the mtD-
NA sequence profile for each sample (51).
This study focused exclusively on the HV1 of the control 
region. The primers used for first round PCR (frPCR) amplifi-
cation flanked the entire HV1 region (nucleotide positions 
16 024-16,365) and were designed to include the primer-
binding sequence, a multiplex identifier (MID) sequence 
used to identify different samples being run together on 
the same plate, and a Fusion Primer sequence for binding 
of amplicon molecules to DNA capture beads, emulsion 
PCR (emPCR), and the pyrosequencing reaction (Figure 1). 
Five different primer sets with 5 different MIDs were de-
signed and used for all frPCR amplifications (Table 1).
The quantity of input DNA from each sample for frPCR was 
20 ng, based on quantification of nuclear DNA. Therefore, 
total mtDNA quantities were unknown, and actual mixture 
ratios were determined empirically. Each amplification in-
cluded 1 × PCR buffer, 10 mM dNTPs, 2.5 units of AmpliTaq 
Gold (all from Applied Biosystems), and 10 pmols of each 
primer (Integrated DNA Technologies, Coralville, Ia, USA). 
Cycling conditions for all amplifications were a 95°C soak 
for 10 minutes followed by 28 cycles of 94°C for 1 min-
ute, 60°C for 1 minute, and 72°C for 1 minute. Following 
frPCR, the concentration of mtDNA amplicon was deter-
mined for each sample by running 20% of the product on 
a 2% agarose gel and comparing the band intensities to 
known standards. Each sample was then diluted to an 
approximate concentration of 1 × 109 molecules/μL us-
ing a formula provided in the 454 Life Sciences pro-FORENSIC SCIENCE 302 Croat Med J. 2011; 52: 299-313
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tocol (49). The typical dilution factor was 10-100, or 1-2 or-
ders of magnitude. Therefore, it is possible that 0.2-2 ng of 
input nuclear DNA would suffice for analysis. Experiments 
to test this supposition are being conducted, as ultimate 
levels of sensitivity will be an important factor for making 
the method operational. Once each sample was diluted 
to 1 × 109 molecules/μL, 10 μL or 10 × 109 molecules were 
pooled for each sample containing a different MID. For the 
5 samples run in each experiment, this resulted in a total 
volume of 50 μL. A total of 2 μL of this pooled set of ampli-
cons was diluted further by combining the 2 μL with 198 
μL of dionized water, or diluted by an additional factor of 
100. Again, this additional dilution step could be eliminat-
ed to further reduce the amount of input DNA used for the 
frPCR. The pooled and diluted amplicons were then run to-
gether through the emPCR and pyrosequencing steps of 
the process.
All samples were processed using the 454 GS Junior Tita-
nium Series Lib-A emPCR Kit. This kit allows for the analysis 
of both strands of the amplicon, enabling the sequence 
data to be confirmed in both directions. Following emP-
CR, the capture beads with bound DNA were enriched. 
The enrichment process (performed according to the 
454 GS Junior manual) (49) uses a second DNA cap-
ture mechanism to separate out beads with and without 
bound emPCR products. This process maximizes the ca-
pacity of useful beads used in the pyrosequencing step. 
The quantity of enriched beads was estimated, and if the 
output was between 500 000 and 2 million beads, the ex-
periment was deemed a success. The enriched pool of 
beads was used for pyrosequencing on the GS Junior in-
strument, performed according to the 454 GS Junior man-
ual (49). Analysis of the resulting mtDNA sequence data 
was  performed  using  the  NextGENe®  software  package 
from  SoftGenetics,  Inc  (State  College,  PA,  USA).  Specific 
modifications were made to the software to address the 
analysis of forensic mtDNA polymorphisms; eg, compari-
son to the Cambridge Reference Sequence (CRS, 25).
By using the MID system to differentiate samples being run 
together on the same pyrosequencing plate, a total of 44 
different experiments were performed for this study over 
9 instrument runs. The first 15 experiments (3 instrument 
runs) were used to determine the threshold for detecting 
mixture  components. Two  individuals  were  selected  for 
each run who did not share mtDNA sequence polymor-
phisms in HV1; the 3 pairs of samples were F12/M15, M9/
M11, and M15/F22. Mixtures of the 2 individuals were made 
in ratios of 1:5, 1:100, 1:250, 1:500, and 1:1000; based on nu-
tAble 1. First round polymerase chain reaction (frPCR) primer sequences for hypervariable segment 1. starting at the 5′-end of each 
primer, fusion primer sequence for forward and reverse emulsion PCR and pyrosequencing is in standard font, followed by multiplex 
identifier sequence in italics and primer binding sequence in bold
Primer sequence
MID1 forward 5′ – GCCTCCCTCGCGCCATCAG ACGAGTGCGT CACCAttAG CACCCAAAGCt – 3′
MID1 reverse 3′ – GtGGtAGGAGGCACtttAGt TGCGTGAGCA GACTCG CCCGACCGTTCCG – 5′
MID9 forward 5′ - GCCTCCCTCGCGCCATCAG TAGTATCAGC CACCAttAG CACCCAAAGCt – 3′
MID9 reverse 3′ – GtGGtAGGAGGCACtttAGt CGACTATGAT GACTCG CCCGACCGTTCCG – 5′
MID10 forward 5′ - GCCTCCCTCGCGCCATCAG TCTCTATGCG CACCAttAG CACCCAAAGCt – 3′
MID10 reverse 3′ – GtGGtAGGAGGCACtttAGt GCGTATCTCT GACTCG CCCGACCGTTCCG – 5′
MID11 forward 5′ – GCCTCCCTCGCGCCATCAG TGATACGTCT CACCAttAG CACCCAAAGCt – 3′
MID11 reverse 3′ – GtGGtAGGAGGCACtttAGt TCTGCATAGT GACTCG CCCGACCGTTCCG – 5′
MID12 forward 5′ – GCCTCCCTCGCGCCATCAG TACTGAGCTA CACCAttAG CACCCAAAGCt – 3′
MID12 reverse 3′ – GtGGtAGGAGGCACtttAGt ATCGAGTCAT GACTCG CCCGACCGTTCCG – 5′
Figure 1.
First round polymerase chain reaction (frPCR) primer design. the squares represent the primer binding sequence, the circles represent the multiplex 
identifier (MId) sequence, and the thick line represents the fusion primer sequence for 454 applications. the length of each primer is 49 nucleotides. the 
total amplicon length is 503 bps; 49 nucleotides of forward and reverse primers +405 bps of hypervariable segment 1 (HV1) representing target sequence 
between nucleotide positions 15 997 and 16 401.303 Holland et al: Resolving mtDNA mixtures and heteroplasmy
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clear DNA quantification values. The samples for each of the 
5 ratios were mixed together pre-frPCR, and primers with 
different MIDs were used so that the 5 mixtures could be 
run together on the GS Junior. Each set of resulting data 
was partitioned with the NextGENe® software by using the 
coded MID sequences, and aligned with the CRS. Forensic 
polymorphisms were identified on the actual sequence as 
shaded nucleotides, and listed in a table format with other 
data, such as the percentage of each polymorphism and 
the number of sequencing reads in the forward and reverse 
directions. Analysis was performed on the mixture samples 
with filters set extremely low to allow for all variants to be 
evaluated. However, we determined that single nucleotide 
differences had to be observed at least 20 times to be con-
sidered reliable during the analysis phase.
A total of 20 experiments (4 instrument runs) were per-
formed on 20 unrelated individuals with 19 different HV1 
haplotypes. One of the 20 samples failed to give accept-
able levels of frPCR product. Therefore, only 19 of these 
samples produced reportable data. These 19 samples were 
run to assess the 454 system’s ability to detect previously 
unseen low-level heteroplasmic variants when compared 
to Sanger sequencing results. To test reproducibility, 4 ex-
periments (a single instrument run) were performed. Two 
samples that had been previously analyzed were run in du-
plicate (F5 and M10), and differentiated with the use of 4 
MIDs; M15 was also run in duplicate in the mixture stud-
ies. These experiments allowed for the assessment of the 
system’s reproducibility when detecting low-level hetero-
plasmic variants, and to determine whether the variants 
were, in fact, truly heteroplasmy as opposed to PCR and/
or sequencing artifacts. The last 5 experiments (a single in-
strument run) involved a comparison of mtDNA sequence 
data  from  5  maternal  relatives.  The  5  relatives  were  a 
grandmother, a daughter and two sons of the grandmoth-
er, and a granddaughter of the grandmother. The mtDNA 
sequence data for these 5 individuals was compared to as-
sess potential differences in minor variants when the major 
sequence is identical.
A single instrument run was conducted by 454 Life Scienc-
es in Branford, CT, USA, using primers designed for foren-
sically relevant STR (D18S51) and Y-STR loci (DYS389 I/II), 
along with primers for the latter half of HV1, or what has 
traditionally been referred to as primer set 2 (PS2) (Table 2). 
Sequence data was generated on the 454 GS FLX Titanium 
instrument. For this experiment, the plate was divided into 
8 different channels for 8 individual experiments. The first 
3 experiments involved 3 different individuals; one female, 
F1, and two male, M1-2. Experiments 4 and 5 were post-
PCR mixtures of a 1:1 ratio of two different samples ampli-
fied with different MIDs. These experiments served as a test 
for the ability of the instrument and the software to par-
tition the data. The final 3 experiments involved pre-PCR 
mixtures of two individuals (M1 and M2), in ratios of 1:1, 
1:5, and 1:20, to illustrate that conventional forensic mix-
tures could be identified and resolved for STR, Y-STR, and 
the PS2 amplicons.
Results
The HV1 mtDNA sequence profile for 25 of the 27 lineages 
analyzed in the current study was generated using both 
the traditional Sanger method and the 454 GS Junior SGS 
approach (Table 3); the PS2 sequence of samples F1, M1, 
tAble 2. First round polymerase chain reaction (frPCR) primer sequences for primer set two (Ps2) of hypervariable segment 1, the 
d18s51 short tandem repeat locus, and the dYs389 I/II loci. starting at the 5′-end of each primer, fusion primer sequence for emul-
sion PCR and pyrosequencing is in standard font, followed by multiplex identifier sequences in italics and primer binding sequence 
in bold
Primer sequence
PS2 MID1 forward 5′ – GCCTCCCTCGCGCCATCAG ACGAGTGCGT AtACttGA CCACCtGtAGtAC – 3′
PS2 MID1 reverse 3′ – GtGGtAGGAGGCACtttAGt TGCGTGAGCA GACTCG CCCGACCGTTCCG – 5′
PS2 MID11 forward 5′ – GCCTCCCTCGCGCCATCAG TGATACGTCT AtACttGA CCACCtGtAGtAC – 3′
PS2 MID11 reverse 3′ – GtGGtAGGAGGCACtttAGt TCTGCATAGT GACTCG CCCGACCGTTCCG – 5′
D18S51 MID1 forward 5′ – GCCTCCCTCGCGCCATCAG ACGAGTGCGT tGACAAA ttGAGACCtGtCtC – 3′
D18S51 MID1 reverse 3′ – GAGGTGTGTGGTCTCTTCAA TGCGTGAGCA GACTCG CCCGACCGTTCCG – 5′
D18S51 MID11 forward 5′ – GCCTCCCTCGCGCCATCAG TGATACGTCT tGACAAA ttGAGACCtGtCtC– 3′
D18S51 MID11 reverse 3′ – GAGGtGtGtGGtCtCttCAA TCTGCATAGT GACTCG CCCGACCGTTCCG – 5′
DYS389 I/II MID1 forward 5′ – GCCTCCCTCGCGCCATCAG ACGAGTGCGT AACtCtCA tCtGtAttAtCtAtG – 3′
DYS389 I/II MID1 reverse 3′ – CCCtAttAACACAAGGAGttC TGCGTGAGCA GACTCG CCCGACCGTTCCG – 5′
DYS389 I/II MID11 forward 5′ – GCCTCCCTCGCGCCATCAG TGATACGTCT AACtCtCA tCtGtAttAtCtAtG– 3′
DYS389 I/II MID11 reverse 3′ – CCCtAttAACACAAGGAGttC TCTGCATAGT GACTCG CCCGACCGTTCCG – 5′FORENSIC SCIENCE 304 Croat Med J. 2011; 52: 299-313
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and M2 was previously evaluated in a pilot study (data not 
shown), although a maternal relative of F1 was run with 
the current study (F9). A total of 4% of the lineages (1 out 
of 25) showed reportable heteroplasmy with the Sanger 
method compared to 44% (11 out of 25) when using the 
SGS approach. A combined total of 15 different nucleotide 
positions showed minor component heteroplasmy: 16093 
(T A), 16111 (CA), 16126 (T), 16128 (T), 16129 (G), 16192 (CA), 
16209 (C), 16222 (T), 16223 (CA), 16261 (CA), 16278 (CA), 
16293 (G), 16298 (TA), 16304 (TA), and 16311 (C and TA), with 
the A in XA annotating that the minor variant is the same 
as the CRS. Many of the sequence positions are consis-
tent with mutational hot spots or positions where forensic 
polymorphisms and heteroplasmy have been observed in 
the past (10,16). A total of 19 observations of heteroplasmy 
were made at these 15 nucleotide positions for the 25 lin-
eages; duplicates were seen at 16093 (T), 16192 (C), 16304 
(T), and 16311 (C and T).
Only one of the 25 lineages (F2) exhibited reportable het-
eroplasmy for both of the sequencing methods. This sam-
ple had approximately 20% T/C heteroplasmy at position 
16311, which was easily identified by the Sanger method 
(Figure 2); the T/C designation indicates that the T is ma-
jor and the C is minor. Unfortunately, the only approach 
for providing meaningful estimates of the percentage of 
heteroplasmy in Sanger data are a physical measurement 
of peak heights. For sample F2, the height of the T peak 
at 16311 was 10 mm on average (using forward and re-
serve data), whereas the average height of the underlying 
tAble 3. the hypervariable segment 1 mitochondrial dNA (mtdNA) profiles for 25 of the 27 lineages; polymorphic nucleotide sites 
are in relation to the Cambridge Reference sequence. the percentage of minor component heteroplasmy at specific sites is provided 
for each sample, when detected
sample
sanger 
mtdNA profile
Percent of minor 
heteroplasmy and site
454 Gs Junior 
mtdNA profile
Percent of minor 
heteroplasmy and site
F2 16069T, 16093C, 16126C, 16261T, 
16274A, 16355T
16311 – 18.4% C 16069T, 16093C, 16126C, 16261T, 
16274A, 16355T
16093 – 3.71% T 16261 – 1.29% C 
16311 – 20.14% C
F3 16069T, 16126C, 16145A, 16172C, 
16261T
Not detected 16069T, 16126C, 16145A, 16172C, 
16261T
Not detected
F4 No polymorphisms Not detected No polymorphisms Not detected
F5 16129A, 16172C, 16223T, 16311C Not detected 16129A, 16172C, 16223T, 16311C 16129 – 0.51% G 16311 – 0.33% T
F7, F12-13, 
M13-14
16192T, 16256T, 16270T Not detected 16192T, 16256T, 16270T 16192 – 2.64%-4.50% C
F8 16223T, 16362C Not detected 16223T, 16362C 16223 – 1.86% C
F9 16356C Not detected 16356C Not detected
F10 16298C Not detected 16298C 16298 – 0.45% T
F16 16126C, 16239T, 16294T, 16296T, 
16304C
Not detected 16126C, 16239T, 16294T, 16296T, 
16304C
Not detected
F25 16343G Not detected 16343G Not detected
F26 16093C Not detected 16093C Not detected
F27 16172C, 16278T Not detected 16172C, 16278T Not detected
M3 16355T Not detected 16355T Not detected
M4 16111T Not detected 16111T 16111 – 0.52% C
M5 16114A, 16129A, 16192T, 16213A, 
16223T, 16278T, 16355T, 16362C
Not detected 16114A, 16129A, 16192T, 16213A, 
16223T, 16278T, 16355T, 16362C
16192 – 3.18% C
M7 16129A, 16223T, 16264T Not detected 16129A, 16223T, 16264T Not detected
M8 16224C, 16311C Not detected 16224C, 16311C Not detected
M9 16301T, 16343G, 16356C Not detected 16301T, 16343G, 16356C Not detected
M10 16304C Not detected 16304C 16209 – 2.62% C 16222 – 2.30% T 
16304 – 2.99% T
M11 16129A, 16223T Not detected 16129A, 16223T Not detected
M12 16069T, 16126C Not detected 16069T, 16126C 16126 – 1.14% T
M15 16093C, 16224C, 16311C Not detected 16093C, 16224C, 16311C 16093 – 3.04% T
M17 16126C, 16294T, 16296T Not detected 16126C, 16294T, 16296T Not detected
M18 16278T, 16304C, 16311C Not detected 16278T, 16304C, 16311C 16128 – 0.52% T 16278 – 0.77% C 
16293 – 0.77% G 16304 – 1.00% T
M19, F22 16069T, 16126C, 16222T Not detected 16069T, 16126C, 16222T Not detected305 Holland et al: Resolving mtDNA mixtures and heteroplasmy
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C peak was 2.25 mm. Therefore, the amount of minor com-
ponent C in the T/C heteroplasmy could be estimated at 
18.4%. Conversely, the SGS data measured the amount of 
the minor component C at 20.14% by dividing the num-
ber of C-reads by the total reads. For all other observations 
of heteroplasmy in the remaining 24 lineages, the minor 
component  did  not  reach  a  level  that  was,  or  typically 
would  be,  observable  with  the  Sanger  method  (Figure 
2); all minor component values were within a measured 
range of 0.33% to 4.50%, or in the range of mixture ratios of 
1:20 to 1:300. In addition, all of the low-level heteroplasmic 
positions had coverage rates of at least 40 reads, with most 
having well over 100 reads. Therefore, these results can be 
considered highly reliable.
The reproducibility of detecting minor component het-
eroplasmy was evaluated by looking at two samples in 
triplicate (F5 and M10), and one sample in duplicate (M15). 
The first sample (F5) had low-level heteroplasmy at posi-
tions 16129 A/G and 16311 C/T. The percentages of het-
eroplasmy for each position were relatively consistent be-
tween and within experiments; 0.51%, 1.06%, and 0.36% 
for 16129 (an average ratio of 1:155), and 0.33%, 1.09%, 
and 1.82% for 16311 (an average ratio of 1:93). The sec-
ond sample (M10) had low-level heteroplasmy at 16209 
T/C, 16222 C/T, and 16304 C/T. The percentage of het-
eroplasmy for each position was, again, relatively consis-
tent between and within experiments; 2.62%, 2.58%, and 
2.32% for 16209 (an average ratio of 1:40), 2.30%, 2.03%, 
and 2.57% for 16222 (an average ratio of 1:44), and 2.99%, 
1.87%, and 0.56% for 16304 (an average ratio of 1:55). The 
last sample (M15) had low-level heteroplasmy at 16093 
C/T. The percentage of heteroplasmy for this position was, 
yet  again,  consistent  between  and  within  experiments; 
3.04% and 3.40% for an average ratio of 1:30. Therefore, 
based on these data, the SGS method as it was employed 
in  this  study  is  reproducible  when  detecting  low-level 
heteroplasmy variants in an approximate range of 0.33%-
tAble 4. A summary of the data for the 3 sets of 5 mixture experiments at the estimated ratios of 1:5, 1:100, 1:250, 1:500, and 1:1000. 
total coverage is the total number of sequencing reads generated by the instrument; minor component percentage is the percent-
age of the total reads that correspond to the minor nucleotide; minor component coverage is the total number of sequencing reads 
generated by the instrument for the minor component; forward:reverse sequence reads is the total number of sequencing reads 
generated by the instrument in the forward and reverse directions; and minor vs total is a reflection that the number on the top 
ratios are minor (eg, 662:363) and the bottom ratios are total (eg, 5425:2946)
experiment 1 (F12:M15) experiment 2 (M9:M11) experiment 3 (M15:F22)
Mixture
total 
coverage
minor component 
percentage
total 
coverage
minor component 
percentage
total 
coverage
minor component 
percentage
1:5   8371 12.24 1950 7.18   11310 16.85
1:100 11126   0.56 2751 0.11   2436   0.86
1:250   7241   0.36 2830 0.11   3959   0.38
1:500   9941   0.24 7357 0.07 25705   0.051
1:1000   5848   0.07 1234 0.16   2991   0.100
minor 
component 
coverage
forward: reverse 
sequence reads 
minor vs total
minor 
component 
coverage
forward: reverse 
sequence reads 
minor vs total
minor 
component 
coverage
forward: reverse 
sequence reads 
minor vs total
1:5   1025 662:363
5425:2946
  140 122:18
1651:299
  1906 1181:725
7492:3818
1:100    6 2 46:16
7910:3216
   3 3:0
2410:341
   2 1 12:9
1783:653
1:250    2 6 19:7
4789:2452
   3 2:1
2329:501
   1 5 9:6
2490:1469
1:500    2 4 14:10
6945:2996
   5 5:0
7012:345
   1 3 8:5
18411:7294
1:1000     4 3:1
3954:1894
   2 1:1
972:262
    3 2:1
1971:1020
actual mixture ratio actual mixture ratio actual mixture ratio
1:5 1:8 1:14 1:6
1:100 1:178 1:917 1:116
1:250 1:278 1:917 1:264
1:500 1:417 1:1428 1:1977
1:1000 1:1428 1:625 1:997FORENSIC SCIENCE 306 Croat Med J. 2011; 52: 299-313
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2.99%. Given the robustness of the data, and the relatively 
low percentage of heteroplasmy being detected, we can 
assume that the method will remain reproducible at high-
er percentages of heteroplasmy.
The total number of sequence reads (ie, the coverage rate), 
along with the percentage of minor component sequence 
or the number of minor component sequence reads, and 
the distribution of minor component reads in both the 
forward and reverse direction, allow for a general assess-
ment of the actual mixture ratio in comparison to the es-
timated ratio that was based on nuclear DNA quantifica-
tion data (Table 4). As expected, the actual ratios were, in 
some cases, quite different from the estimated values. In 
some cases, these values were quite lower than expected, 
which further enhances the value of the data. These data 
can also be used to assess the level of reliability for identi-
fying minor components at the different ratio levels based 
on coverage rates and the confirmation of sequence data 
on both strands of DNA. For example, the minor compo-
nent was easily distinguishable in all 6 mixtures with a ratio 
of 1:5 (20%) and 1:100 (1%), as the total number of minor 
reads ranged from 21 to 1906, and the ratio of forward to 
reverse reads was comparable to the ratio of total reads. 
The actual values for these two target ratios ranged from 
1:6 to 1:8 for the 1:5 mixture, and 1:116 to 1:178 for the 
1:100  mixture;  the  second  mixture  experiment  yielded 
considerably lower read numbers, so these data were in-
terpreted with caution.
In general, the ratio of forward to reverse reads for mi-
nor component sites when compared to the total 
was quite consistent. For example, the average ratio of for-
ward to reverse reads for the two minor component sites 
observed in sample F5 was 2.66, compared to 2.75 for the 
total ratio. The difference between these two values is 3.3%. 
A similar result was seen for the average ratio of forward to 
reverse reads for the 3 minor component sites observed in 
sample M10; 1.76 vs 1.84, 4.4%. However, there was vari-
ability observed in the ratio of values for other samples, oc-
curring most often for samples containing a single minor 
component site. For example, the ratios for sample M12 
gave the highest differences, 6.86 (minor) vs 2.20 (total), for 
a difference of 212%. While this is clearly a significant dif-
ference in a mathematical sense, the number of total reads 
for the minor component site in this sample was 165, the 
percentage of the minor variant was 1.14%, and this is a 
known site where sequence difference occur between in-
dividuals, so it is unlikely that this observation was due to a 
PCR or sequencing error.
While the reproducibility experiments were useful in ad-
dressing the reliability of reported data, we did an assess-
ment of potential PCR and sequence errors in an attempt 
to establish thresholds and/or filters. For the current study, 
insertions and deletions were not considered. Sequence 
changes (forensic polymorphisms), in relation to the CRS, 
were  captured  and  assessed  individually. The  following 
considerations were made: 1) the change was not seen in 
other non-related data conducted during the same run, 2) 
the change was plausible based on the actual sequence 
data, looking for things like miss alignment, 3) the change 
was seen more than 40 times, 4) the ratio of forward to 
reverse reads was consistent when comparing the minor 
site ratio to the total value, and 5) the change was a transi-
tion vs a transversion. If two or more of these criteria were 
violated, the change was not reported. Interestingly, in one 
experiment (samples from 5 different individuals), we ob-
served sequence changes at the following 7 positions in 
all 5 samples: 16042 T, 16095 A, 16145 T, 16148 A, 16174 
A, 16250 A, and 16328 A. Each of these changes is also a 
transversion from the CRS, and in some instances violat-
ed at least one other criterion as stated above. Therefore, 
these changes were not reported. It is unclear whether 
these were PCR or sequencing errors, although since none 
of these 7 changes was seen in other samples in other runs 
(including for runs conducted with the same reagent lot 
number), it seems likely that these were PCR-based errors 
for this one set of data.
For the 1:250 mixtures, the minor component was easily 
detected when the coverage rate was at least 5000, but 
Figure 2.
Heteroplasmy at positions 16 093, 16 261, and 16 311 of sample F2, as 
observed when using the sanger method of dNA sequencing. the only 
position where heteroplasmy would have been called by the majority of 
forensic scientists is 16 311; laboratories using instruments with low lev-
els of signal to noise may have called position 16 093. the correspond-
ing percentages of heteroplasmy observed in the second generation se-
quencing data were, 3.71%, 1.29%, and 20.14%, respectively.307 Holland et al: Resolving mtDNA mixtures and heteroplasmy
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was still readily observed even when coverage dropped to 
2830 reads. The actual ratios for experiments 1 and 3 were 
1:278 and 1:264, respectively. These data were supported 
by the number of minor reads, and the ratio of forward to 
reverse reads when compared to the ratio of total reads. 
The ability to detect minor component sequences in 1:500 
and 1:1000 mixtures was dependent on coverage rate (ide-
ally at least 10 000 and 20 000, respectively), which was not 
met in most instances during this study. Only twice in the 
6 experiments did the coverage reach or approach 10 000; 
9941 in experiment 1 and 25 705 in experiment 3, both for 
the 1:500 mixture ratio. In experiment 1, the number of mi-
nor reads reached 24, and resulted in a measured mixture 
ratio of 1:417. In addition, the ratio of forward to reverse 
reads was consistent with the total read ratio. However, in 
experiment 3, the number of minor reads only reached 13, 
even with more than 25 000 total reads, for a measured ra-
tio of 1:1977. Therefore, without greater coverage, it is dif-
ficult to reliably report minor components in mixture ratios 
of 1:500 to 1:1000.
The family study yielded results with limited value. All 5 
members had the 16192 T, 16256 T, and 16270 T forensic 
polymorphisms. In addition, they each had SGS-detectable 
levels of heteroplasmy at position 16192 (C). The range of 
heteroplasmy was 2.64%-4.50%, so this position was not 
able to differentiate individuals within the same lineage. 
In addition, very low-level heteroplasmy was detected at 
position 16129 (A/G), but too low to be considered reli-
able enough to report; the grandmother and mother had 
0.14%-0.48% heteroplasmy, but only 3-7 reads (3/0 to 4/3, 
forward/reverse), and the grandchildren had 0.08%-0.31% 
heteroplasmy, with 4-7 reads (3/1, 4/0, and 5/2). If this het-
eroplasmy was, in fact, shared by all family members, it too 
would not be a useful position for discriminating between 
members.
The amplicons for STR, Y-STR, and mtDNA loci could be 
pooled together using the MID system, their sequences 
generated in a single instrument run, and the resulting 
data partitioned into different samples, different loci and 
different allelic “bins.” The PCR primer binding sequence 
functions as the locus identifier, the MID serves as the sam-
ple identifier, and the fusion sequence is used for the py-
rosequencing process. Figure 3 is an illustration of the abil-
ity of the NextGENe software to partition the allelic data for 
D18S51 through comparison and alignment to reference 
alleles. The data in Figure 3 also illustrate that conventional 
mixtures can be interpreted by using read numbers. This 
is analogous to using relative fluorescence units for con-
Figure 3.
short tandem repeat results for the d18s51 locus of two samples mixed in a pre-polymerase chain reaction ratio of 1:1. the d18 profile for individual one 
was 13,14 and 14,17 for individual two. the 3 gray-shaded areas labeled in the figure are representative of the sequence density for alleles 13, 14, and 
17; ~ 1000-2500 sequences for each allele. the cross above the 14 allele indicates which sequence is being displayed in the window below; sequences 
1-28 for allele 14. the sequence density for allele 14 is illustrative of 2 doses of that allele. the area enclosed by the box in the window below is the 14 
copies of the stR repeat, AGAA, for the 14 allele; for sequences 6-10. the numbered sequence above the window is a reference used to partition the se-
quences associated with the 14 allele away from other alleles.FORENSIC SCIENCE 308 Croat Med J. 2011; 52: 299-313
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ventional STR analysis. The “profile” in the figure is from a 
mixture of 2 individuals in an estimated ratio of 1:1. The 
measured ratio was 1:0.92. The data for the 1:5 and 1:20 
mixtures  were  consistent  with  these  findings  (data  not 
shown). The advantage of using SGS to generate STR re-
sults is that both length-based and sequence-based infor-
mation can be captured at the same time. In addition, since 
PCR fragment size is eliminated as a factor in the analysis 
of the amplicon, the number of target loci can be greatly 
increased when compared to conventional capillary elec-
trophoresis methods of STR analysis.
Finally, during the course of completing the recent work 
on this project, it was determined that chimeric mtDNA 
sequences were being produced through jumping PCR. 
This was presumably happening during the frPCR pro-
cess, however, we have not ruled out the emPCR step. 
Data for the M15/F22 mixtures, in ratios of 1:5 and 1:100, 
serve  as  an  illustration  of  this  phenomenon  (Table  5). 
An example of the chimeric data shows two interesting 
trends (Figure 4). First, when the minor component is in 
higher percentages (1:5), there is less jumping PCR ob-
served. Second, if the data are “pooled,” as happens dur-
ing Sanger sequencing, the percentage of each compo-
nent  is  consistent  with  expected  values. The  distance 
between the polymorphisms for both M15 and F22 helps 
to explain the data (Figure 5). It is more likely for “recombi-
nation” like events during jumping PCR to occur between 
16126 C and 16222 T, and between 16224 C and 16311 
C, than between 16069 T and 16126 C. The data supports 
this prediction (Table 5).
Figure 4.
A chimeric mitochondrial dNA sequence for a sample from a 1:100 mixture of M15 and F22. the second sequence from the top has the 16069 t, 16126 
C, and 16222 t polymorphisms of the minor component; highlighted by the NextGeNe software. the second sequence from the bottom is a chimeric 
product that contains the 16 069 t and 16 126 C from the minor component, and the 16 224 C and 16 311 C polymorphisms from the major component. 
this is referred to as a Minor Front, Major back chimeric sequence. the missing C’s at position 16 224 for the 4th, 5th, and 7th sequences listed below are 
indicative of the difficulties of the 454 approach to resolve homopolymeric stretches of greater than 4 C’s in a row.
Figure 5.
the distance between mitochondrial dNA polymorphisms in the major and minor components of a 1:5 or 1:100 mixture of M15 and F22. the major 
component profile from M15 has 16093 C/t heteroplasmy, 16224 C, and 16311 C, and the Minor component profile from F22 has 16069 T, 16126 C, and 
16222 T.
tAble 5. A summary of the complete and chimeric sequences 
observed in the 1:5 and 1:100 mixtures for samples M15 
(major) and F22 (minor). the front and back designations 
reflect the first and second halves of hypervariable segment 
1, respectively. the mtdNA sequence for the major and minor 
components can be found in table 3 and Figure 4
samples M15 and F22 1:5 ratio 1:100 ratio
Total sequences analyzed 1028 (of 11 310) 2436
Complete minor sequences   130    6
Major front, minor back sequences   2 1    5
Minor front, major back sequences   2 2    9
069T + major sequences    6    2
069C+ minor sequences   2 3    9
Major +311T sequences   1 6    2
Minor +311C sequences    4    2309 Holland et al: Resolving mtDNA mixtures and heteroplasmy
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dIsCussION
The SGS platform of 454 Life Sciences, including the GS Ju-
nior instrument, produces reliable and reportable results 
for the analysis of mtDNA sequence data. As we reported 
here, the forensic mtDNA sequence profile of HV1 was cor-
rectly analyzed for 25 different maternal lineages, across 
30 different individuals. In addition, the results clearly il-
lustrate the added levels of observed heteroplasmy that 
can be achieved when using the SGS approach. When us-
ing the conventional Sanger dideoxy-terminator method, 
only one of these 25 lineages exhibited reportable hetero-
plasmy; a 4% rate. However, the SGS approach identified 
low-level heteroplasmy for 11 of the 25 lineages; a 44% 
rate of identifiable and reportable heteroplasmy. The nu-
cleotide positions where heteroplasmy was observed are 
consistent with mutational hot spots or sites where foren-
sic polymorphisms (in comparison to the CSR) and het-
eroplasmy have been observed in past studies (10,16). In 
particular, when the sensitivity level of heteroplasmy de-
tection is elevated (eg, when using a denaturing gradient 
gel electrophoresis approach), many of the same sites of 
heteroplasmy identified in the current study have been 
previously reported (16).
The distribution of heteroplasmic sites spanned the entire 
range of HV1. In addition, there was a relatively even distri-
bution of minor component sites that corresponded to the 
CRS, as opposed to those that differed from the CRS; 9 ob-
servations vs 7, respectively. This is an important observa-
tion when attempting to differentiate individuals with the 
same primary haplotype, as it may be expected that low-
level heteroplasmy would exist at polymorphic positions. 
However,  minor  sequences  with  non-CRS  nucleotides 
could be the result of widespread lineage-based hetero-
plasmy, or could be de novo changes in the sequence 
that occurred during early fetal development. For relatives 
within the same lineage, one might expect that the chanc-
es are more likely that non-CRS variants would be shared 
by other family members. While the family data generated 
for our study were not illustrative of the notion, the over-
all rate of low-level heteroplasmy detection reported in 
Table 3 suggests that it would be possible to differentiate 
between family members. Further studies are needed to 
explore a greater number of lineages, and sequence addi-
tional family members within the same lineage. Nonethe-
less, when faced with two reference sources in a forensic 
case, each of which has the same control region sequence, 
the prospects for tapping into low-level heteroplasmy to 
differentiate the two are high.
Any  concerns  regarding  the  reliability  of  the  sequence 
data generated with the 454 GS Junior SGS approach were 
at  least  partially  addressed  through  the  reproducibility 
studies reported here. Multiple samples were run in either 
duplicate or triplicate, with results that confirmed the posi-
tions of heteroplasmy, and at very similar component per-
centages. Therefore, PCR and/or sequencing artifacts were 
ruled out as the source of the relatively high rate of het-
eroplasmic activity. In addition, the coverage rates and to-
tal number of reads for all heteroplasmic variants reported 
in Table 3 were high. In particular, all reported instances 
of low-level heteroplasmy resulted from at least 40 reads 
of sequence (most with more than 100 reads), and with 
a balanced ratio of forward and reverse reads when com-
pared to the total ratio of forward and reverse reads. These 
data and observations allow for the development of initial 
standards for reporting low-level heteroplasmic variants in 
a forensic setting.
Based on the results from this study, we would recom-
mend reporting low-level variants when at least 40 reads 
have been generated, and when the ratio of forward to re-
verse reads is consistent with the total ratio. Therefore, for 
mixtures of 1:100, 1:250, 1:500, and 1:1000, the coverage 
would need to be at least 4000, 10 000, 20 000, and 40 000, 
respectively. This level of coverage is well within the capa-
bility of the GS Junior instrument. However, a desire to in-
crease coverage rates would drive down throughput and 
drive up costs. The reagent cost per run is currently less 
than US $1000, and the instrument capacity ranges from 
50 000-100 000  reads  per  run. Therefore,  if  detection  of 
low-level variants from ratios of 1:1000 were desired, the 
capacity per run would be 1-2 samples, with a reagent cost 
of less than US $500-1000 per sample. If a ratio of 1:250 
were suitable, the number of samples per run would go up 
to 5-10, and the cost per sample would drop to less than 
US $100-200. Given that multiple amplifications would be 
needed to cover the entire control region, and including 
the potential for replicate testing, the total cost per sample 
could run as high as US $800-1600. In addition, the over-
all throughput of the system is lower than conventional 
methods currently in place. Nonetheless, the significantly 
increased level of heteroplasmy detection is enough of a 
value-added feature to make this an attractive approach 
when attempting to increase discrimination potential or 
differentiate between individuals with the same primary 
haplotype.
The results of the mixture study further validate that 
the 454 GS Junior can reliably detect minor compo-FORENSIC SCIENCE 310 Croat Med J. 2011; 52: 299-313
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nent variants. Mixtures, including heteroplasmic variants, 
were detected routinely down to a component ratio of 
1:250. In doing so, at least 40 minor variant copies were 
observed with a coverage rate of at least 5000 sequences. 
However, the concept of resolving mixtures is quite differ-
ent than identifying low-level variants. The goal for the lat-
ter is to identify low-level single nucleotide variants below 
the surface of a primary sequence profile. For a mixture, 
the goal is to resolve individual mtDNA haplotypes from 
one another despite the ratio of the 2 (or more) compo-
nents found in the mixture. Following this logic, while the 
read number, the ratio of forward to reverse reads, and the 
overall coverage are all directly proportional to the success 
of the typing approach, read number in relation to cover-
age rates for mixtures could be more important. Of course, 
mixture analysis is also affected by the introduction of for-
eign sources of DNA during the analysis process, which 
is especially relevant when considering SGS data. Histori-
cally, forensic mtDNA laboratories using the Sanger DNA 
sequencing method have been able to measure the rate 
of contamination in negative controls; as high as 5%. With 
SGS, it is anticipated that this rate will increase; approxi-
mately 10% in our hands. However, the effects of this con-
cern will be dependent on where the thresholds are set 
for acceptance of minor component sequence as report-
able data. Therefore, given the capacity and throughput of 
the GS Junior, and our current understanding of the results 
generated from this instrument, minor ratios above 1:100 
would be desirable for confidently resolving mixture com-
ponents.
To date, only one operational system has emerged that can 
resolve mtDNA mixtures (39,41). The electrospray ioniza-
tion mass spectrometry (ESI-MS) approach from IBIS Biosci-
ences is capable of resolving mtDNA mixtures with com-
ponent ratios as low as 1:20 (41), and has been employed 
in a number of forensic laboratories performing mtDNA 
analysis across the United States. The principle differenc-
es between the ESI-MS and SGS systems are an inability of 
the ESI-MS to identify the exact location where a sequence 
difference exists, and the inability of the SGS system to 
fully resolve homopolymeric stretches and length hetero-
plasmy. The ESI-MS system generates the precise molecu-
lar mass of each pool of amplicons to identify species with 
different sequence content. However, the location of se-
quence differences can only be implied. In contrast, the 
pyrosequencing approach of the 454 SGS system results 
in primary sequence information, but provides poor res-
olution of homopolymeric sequences, and reveals PCR 
and sequencing artifacts that will require a filtering 
mechanism to eliminate their consideration during anal-
ysis; similar to filters needed for STR stutter and spectral 
bleed. Therefore, at this point in time, neither system can 
provide the complete information necessary to make pre-
cise interpretations across the entire control region. How-
ever, given the complexities of mtDNA mixture deconvo-
lution, the SGS approach may be more desirable, since it 
provides  primary  sequence.  In  addition,  the  ESI-MS  ap-
proach from IBIS Biosciences, while commercially available, 
would be cost-prohibitive for most forensic laboratories, as 
both the instrument and reagent costs are high, and the 
throughput is approximately the same as the GS Junior. 
Nonetheless, either approach allows for the deconvolu-
tion of mtDNA mixtures, which has not been available in 
the past.
The strengths and limitations of the discrimination poten-
tial of conventional mtDNA testing have been well docu-
mented (2). Increasing the discrimination level has been 
attempted by looking outside of the HV1 and HV2 regions, 
and expanding the scope of analysis to the coding region 
(for example, 26,29). However, it has also been well doc-
umented that tapping into the underlying levels of het-
eroplasmy in the control region is an excellent method for 
enhancing the discrimination of the typing system (13). 
In the identification case of Nicholas Romanov, the pres-
ence of heteroplasmy in the Romanov family allowed for 
the calculation of a likelihood ratio (LR) that took both the 
haplotype frequency and the probability of observing het-
eroplasmy at any one position along the mtDNA control 
region into account. The LR for identity of the Tsar when 
based strictly on the haplotype of the skeletal remains was 
calculated as 150, and the LR for the presence of a hetero-
plasmic sequence shared by two brothers was calculated 
as 2500 (Nicholas and Georgij Romanov). Therefore, since 
these two events were considered to be independent of 
one another, the LR for the mtDNA evidence was 375 000 
more likely if the remains were, in fact, those of Nicholas 
Romanov. Similar calculations could be generated in foren-
sic cases to assess the weight of observing low-level het-
eroplasmic variants that are shared by the evidence and a 
reference profile.
The presence of chimeric mtDNA sequences in our data, 
presumably produced through jumping PCR, was not an 
unexpected occurrence. This has been observed in a num-
ber of instances in other laboratories (52-54, and personal 
communication from Walther Parson, Innsbruck, Austria), 
mainly  when  dealing  with  ancient  DNA.  Methods  such 
as single-molecule PCR (smPCR) have distinct advantag-311 Holland et al: Resolving mtDNA mixtures and heteroplasmy
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es over conventional vector-based cloning techniques or 
SGS, as they avoid PCR-related artifacts, preferential allelic 
amplifications, and jumping PCR. However, in forensic in-
vestigations, this is somewhat impractical. We are in the 
process of investigating why the jumping PCR is occurring 
in our system, and more importantly, how it can be miti-
gated. Given that we used considerably more input DNA 
than necessary for the frPCR process, and that there is less 
jumping PCR observed when the minor component is in 
higher percentages (eg, 1:5), it is quite possible that by sim-
ply reducing template DNA we can eliminate jumping PCR 
from happening. However, if further steps are necessary, 
we are also evaluating how to modify the PCR conditions 
to generate a similar effect; for example, by increasing the 
time of extension or by looking at different polymerases. It 
will be important to address this issue if the technique is 
to become operational in forensic DNA laboratories. The 
greatest effect of the jumping PCR phenomenon will be 
on mixture interpretation, as this type of analysis requires 
the production of full length sequences from a single con-
tributor.  Nonetheless,  for  detection  of  low-level  hetero-
plasmic variants, if the SGS data are “pooled” as happens 
during Sanger sequencing, the percentage of each com-
ponent remains consistent with expected values.
While the future of second generation DNA sequencing in 
forensic cases is still under investigation, it is clear that this 
technology has the potential to expand the number and 
types of loci being analyzed together. For example, results 
from out pilot study clearly illustrate that sequence of am-
plicon targets from STR, Y-STR, and mtDNA loci can be gen-
erated at the same time. Using the expanded format of 454 
Life Sciences (FLX), this could provide a cost-effective and 
rapid way to database offender samples for an expanded 
list of autosomal and lineage markers, as well as markers for 
human morphological features and geo-profiling; reagent 
costs of less than US $20 per sample for more than 50 loci 
of data have been made (50). Of course, the newer tech-
nologies of third generation sequencing (eg, single mol-
ecule sequencing from the Pacific Biosciences RS and the 
Ion Torrent PGM system) will need to be evaluated closely 
to determine whether they possess solutions to the limi-
tations of the currently available systems. Hence, while it 
has been more than two decades since DNA testing has 
emerged on the scene, this is an exciting time in the con-
tinuing evolution of the forensic DNA community.
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